---
figid: PMC3432651__nihms390711f2
figtitle: Involvement of the target of rapamycin (mTOR) pathway in human disease syndromes
organisms:
- NA
organisms_ner:
- Drosophila melanogaster
- Homo sapiens
pmcid: PMC3432651
filename: nihms390711f2.jpg
figlink: /pmc/articles/PMC3432651/figure/F2/
number: F2
caption: Involvement of the target of rapamycin (mTOR) pathway in human disease syndromes.
  Germline mutations that affect target of rapamycin complex 1 (mTORC1) activity are
  found in syndromes associated with deregulated cell growth. Tuberous sclerosis,
  Von Hippel–Lindau disease (VHL), and Peutz–Jeghers syndrome directly affect mTORC1
  activation without impacting PI3K (phosphatidylinositol 3-kinase)-Akt, whereas neurofibromatosis
  and the Cowden, Proteus, and Bannayan–Riley–Ruvalcaba syndromes involve PI3K-Akt
  dysregulation, indirectly leading to hyperactivation of mTORC1 and also affecting
  other downstream effectors. Remarkably, a rare syndrome associated with an almost
  complete loss of function of the Ragulator component LAMTOR2/p14 is the only known
  syndrome that affects amino acid-dependent activation of mTORC1, and the only syndrome
  that leads to mTORC1 hypoactivity.
papertitle: 'Amino acids and mTORC1: from lysosomes to disease.'
reftext: Alejo Efeyan, et al. Trends Mol Med. ;18(9):524-533.
year: ''
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9471996
figid_alias: PMC3432651__F2
figtype: Figure
redirect_from: /figures/PMC3432651__F2
ndex: a2554735-dea1-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC3432651__nihms390711f2.html
  '@type': Dataset
  description: Involvement of the target of rapamycin (mTOR) pathway in human disease
    syndromes. Germline mutations that affect target of rapamycin complex 1 (mTORC1)
    activity are found in syndromes associated with deregulated cell growth. Tuberous
    sclerosis, Von Hippel–Lindau disease (VHL), and Peutz–Jeghers syndrome directly
    affect mTORC1 activation without impacting PI3K (phosphatidylinositol 3-kinase)-Akt,
    whereas neurofibromatosis and the Cowden, Proteus, and Bannayan–Riley–Ruvalcaba
    syndromes involve PI3K-Akt dysregulation, indirectly leading to hyperactivation
    of mTORC1 and also affecting other downstream effectors. Remarkably, a rare syndrome
    associated with an almost complete loss of function of the Ragulator component
    LAMTOR2/p14 is the only known syndrome that affects amino acid-dependent activation
    of mTORC1, and the only syndrome that leads to mTORC1 hypoactivity.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - CkIIbeta
  - Andorra
  - Anp
  - Acam
  - Pten
  - Nf1
  - Mer
  - ras
  - Ras64B
  - Ras85D
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - Akt
  - SNF4Agamma
  - AMPKalpha
  - Tsc
  - Tsc1
  - Lkb1
  - Eye
  - ey
  - cac
  - Lamtor1
  - MED21
  - Lamtor2
  - MP1
  - Lamtor3
  - RagC-D
  - RagA-B
  - Crtc
  - Rheb
  - Vhl
  - sima
  - PTEN
  - NF1
  - NF2
  - KRAS
  - HRAS
  - NRAS
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - AKT1
  - AKT2
  - AKT3
  - PRKAA1
  - PRKAA2
  - PRKAB1
  - PRKAB2
  - PRKAG1
  - PRKAG2
  - PRKAG3
  - SLC12A3
  - TSC1
  - TESC
  - TSC2
  - STK11
  - CDKN2C
  - UBE2I
  - MAFK
  - EEF1E1
  - ZNF197
  - ATRAID
  - LAMTOR1
  - TPPP2
  - H3P12
  - CDKN2A
  - S100A9
  - CDK2AP2
  - SUB1
  - RPP14
  - LAMTOR2
  - SF3B6
  - H3P8
  - LAMTOR3
  - PITRM1
  - RRAGD
  - RRAGC
  - RRAGA
  - RRAGB
  - MTOR
  - RPTOR
  - RHEB
  - RHEBP1
  - CORD1
  - VHL
  - HIF1A
  - Cancer
  - Lung cancer
---
